You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR CANCIDAS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CANCIDAS

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00105144 ↗	Study of Micafungin in Patients With Invasive Candidiasis or Candidemia	Completed	Astellas Pharma Inc	Phase 3	2004-09-01	The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	GTEI		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	SEMICYUC		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	PETHEMA Foundation		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00404092 ↗	Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Completed	University of Cologne	Phase 2	2006-10-01	This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CANCIDAS

Condition Name

Chart
Table

Condition Name for CANCIDAS
Intervention	Trials
Fungal Infection	7
Mycoses	5
Candidemia	5
Candidiasis	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CANCIDAS
Intervention	Trials
Mycoses	14
Infections	8
Infection	8
Candidiasis	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CANCIDAS

Trials by Country

Map
Table

Trials by Country for CANCIDAS
Location	Trials
United States	151
Canada	25
China	15
Spain	15
Brazil	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CANCIDAS
Location	Trials
Michigan	8
California	6
Texas	6
Pennsylvania	6
Ohio	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CANCIDAS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CANCIDAS
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	8
Phase 2	5
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CANCIDAS
Clinical Trial Phase	Trials
Completed	13
Terminated	2
Unknown status	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CANCIDAS

Sponsor Name

Chart
Table

Sponsor Name for CANCIDAS
Sponsor	Trials
Astellas Pharma Inc	3
Cidara Therapeutics Inc.	2
Merck Sharp & Dohme Corp.	2
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CANCIDAS
Sponsor	Trials
Other	14
Industry	12
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.